MENLO THERAPEUTICS INC's ticker is MNLO and the CUSIP is 586858102.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $2,397,000 | -1.5% | 516,619 | -4.9% | 0.00% | – |
Q3 2019 | $2,434,000 | -32.0% | 543,392 | -9.0% | 0.00% | -100.0% |
Q2 2019 | $3,578,000 | -24.0% | 597,247 | -0.4% | 0.00% | 0.0% |
Q1 2019 | $4,706,000 | +90.8% | 599,434 | +0.1% | 0.00% | – |
Q4 2018 | $2,467,000 | -58.2% | 598,834 | -0.0% | 0.00% | -100.0% |
Q3 2018 | $5,899,000 | – | 598,934 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
venBio Partners LLC | 1,461,552 | $11,473,000 | 9.29% |
Vivo Capital, LLC | 4,011,236 | $31,488,000 | 3.14% |
DAFNA Capital Management LLC | 600,030 | $4,710,000 | 2.03% |
GREAT POINT PARTNERS LLC | 2,057,027 | $16,148,000 | 1.60% |
MANGROVE PARTNERS IM, LLC | 561,138 | $4,405,000 | 0.59% |
Alambic Investment Management, L.P. | 66,996 | $526,000 | 0.22% |
FIRST MANHATTAN CO. LLC. | 2,256,903 | $17,716,000 | 0.10% |
Orbimed Advisors | 633,920 | $4,976,000 | 0.08% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 198,451 | $1,558,000 | 0.06% |
Baker Brothers Advisors | 700,000 | $5,495,000 | 0.04% |